BEBT-756 is designed to deliver dual APP/MAPT siRNAs specifically to neurons to treat Alzheimer’s disease. Preclinical studies demonstrate significant gene silencing of APP and MAPT (tau) in key brain regions, addressing two critical hallmarks of Alzheimer’s pathology. This dual siRNA targeting approach offers the potential for enhanced efficacy by simultaneously inhibiting both pathways, potentially slowing disease progression more effectively. Furthermore, siRNA therapeutics may complement amyloid-targeting antibodies, which primarily block downstream pathological aggregates formed during advanced, irreversible stages of the disease. By reducing APP and MAPT mRNA levels, siRNA therapy tackles the root cause, directly decreasing the production of these culprit proteins.